Drug Profile
Research programme: pegylated therapeutics - Mountain View Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Mountain View Pharmaceuticals
- Class
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Parenteral)
- 11 Jun 2012 Preclinical trials in Multiple sclerosis in USA (Parenteral)